Pliant Therapeutics (PLRX) vs Rein Therapeutics (RNTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Pliant Therapeutics (PLRX) has outperformed Rein Therapeutics (RNTX) over the past year, losing 34.6% versus a loss of 44.7%. Over five years, PLRX leads with a -94.4% price change compared with -96.2% for RNTX. Rein Therapeutics is the larger company by market cap ($68.0 million vs $63.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PLRX | RNTX |
|---|---|---|
| Share price | $1.03 | $0.7886 |
| Market cap | $63.47M | $68.03M |
| 1-day change | +2.51% | +2.51% |
| YTD return | -18.03% | -33.68% |
| 1-year return | -34.64% | -44.65% |
| 5-year return | -94.44% | -96.19% |
| EPS (TTM) | $-1.50 | $-1.68 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.95 | $2.18 |
| 52-week low | $0.97 | $0.694 |
| Distance from 52-week high | -47.44% | -63.83% |
| Analyst consensus | none | none |
| Avg. price target upside | +95.12% | +660.84% |
| Average volume | 477.96K | 430.81K |
| Shares outstanding | 61.92M | 86.27M |
| Employees | 49 | 10 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PLRX has outperformed RNTX by 10.0 percentage points over the past year.
About Pliant Therapeutics
PLRX stock →Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
About Rein Therapeutics
RNTX stock →Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
PLRX vs RNTX FAQ
Which is bigger, Pliant Therapeutics or Rein Therapeutics?
Rein Therapeutics (RNTX) is larger, with a market capitalization of $68.03M compared with $63.47M for Pliant Therapeutics (PLRX).
Which stock has performed better over the past year, PLRX or RNTX?
PLRX returned -34.64% over the past 12 months, compared with -44.65% for RNTX (price return, excluding dividends). Past performance does not predict future results.
Are Pliant Therapeutics and Rein Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.